Please login to the form below
Lupin
This page shows the latest Lupin news and features for those working in and with pharma, biotech and healthcare.
Boehringer links up with Trutino for cancer R&D
In September 2019, the German drugmaker also made a $720m play for a MEK inhibitor from India’s Lupin that it is looking to pair with its stable of KRAS inhibitors. ... The Lupin deal came only a few short weeks after Boehringer partnered with The
Latest news
-
Boehringer bolsters KRAS push with $720m Lupin deal
Signs of progress in the field are emerging. Boehringer Ingelheim has licensed a MEK inhibitor from India’s Lupin that it intends to pair with its stable of KRAS inhibitors, a ... For Lupin, Boehringer is the second big biopharma partner for its
-
Biogen files Tecfidera follow-up in the US
Earlier this month Indian drugmakers Lupin Labs and Shilpa Medicare both won tentative FDA approval for generic dimethyl fumarate capsules, although they have not indicated when they intend to place the
-
India denies Vertex patent on cystic fibrosis drug Orkambi
The patent was opposed by the Indian Pharmaceutical Alliance (IPA), a trade organisation representing India's larger pharmaceutical companies, including Cipla, Dr Reddy's Labs, Lupin, Nicholas Piramal, Ranbaxy and Wockhardt.
-
Pfizer inks $360m deal to buy InnoPharma
Other notable M&A activity in the sector includes Par Pharma's $490m deal to buy JHP Pharmaceuticals in January, Lupin Laboratories' agreement to buy Nanomi of the Netherlands the following
-
EU hits Servier and generic firms with €428m 'pay-for-delay' fine
The generics companies implicated in the scandal - Niche/Unichem, Matrix (part of Mylan), Teva, Krka and Lupin - are facing penalties of 97m between them.
More from news
Approximately 2 fully matching, plus 24 partially matching documents found.
Latest Intelligence
-
Deal Watch August 2016
165. Shionogi (JP). Kyowa (JP) (Lupin). Asset acquisition Japan. 21 branded products in Japan with $90m sales.
-
Pharma deals in July 2015
The consolidation in the generics industry has also increased with Lupin's acquisition of the US generics company Gavis for $880m at a high sales multiple of nine but which has ... In July Lupin also acquired a factory in Russia and a speciality product
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest appointments
-
Minoyrx Therapeutics appoints chief medical officer
Dr Uwe Meya joins from Lupin Atlantis Holdings. Spanish orphan disease specialist Minoryx Therapeutics has appointed Dr Uwe Meya as its new chief medical officer. ... He joins the Barcelona-based drug development company from Lupin Atlantis Holdings,
-
Lupin appoints Thierry Volle president for EMEA
He moves to the company from Vifor. Mumbai-based pharma company Lupin has appointed Thierry Volle to lead its Europe, Middle-East and Africa operations as president. ... Vinita Gupta, Lupin's chief executive officer, said: "We are delighted to have
-
Dr Maurice Chagnaud appointed as new CEO of Polpharma
He will join the company next week from Lupin where he was a group president with an inhalation remit for Europe, Russia &CIS. ... We are impressed by the extensive experience of Mr Chagnaud, gained in international companies such as Merck Generics, Teva
-
Lupin names chief corporate development officer
Theresa Stevens has experience at Novartis and Aptalis. Lupin has appointed Theresa Stevens as chief corporate development officer for its global operations. ... Lupin's decision to hire Stevens follows its appointment earlier this year of Teva's Dr
-
Lupin appoints European president
countries. He will also be responsible for developing Lupin's core strategy for inhalation across all developed markets. ... Prior to joining Lupin, Dr Chagnaud was senior VP, Central and Eastern Europe, at Israel-based Teva.
More from appointments
Approximately 3 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Country Manager, Healthcare Communications Agency, Germany
-
Highly competitive salary
- Sanofi halts recruitment for trials assessing MS treatment
- bluebird bio reveals plans to launch two gene therapies
- AstraZeneca and Daiichi Sankyo receive FDA approval for lung cancer drug
- ONS data reveals significant decrease in COVID-19 antibodies
- Bristol Myers Squibb and GentiBio in $1.9bn deal to develop IBD therapies
- UK government’s ‘science superpower’ ambitions to fail without clear plan, Lords committee warns
- WHO releases interim statement on COVID-19 vaccination for children and adolescents
- Novartis reports death of two patients treated with Zolgensma
- The impact of COVID-19 on the fight against AMR
- NHS bowel cancer checks reach record-high following death of Dame Deborah James
- Environment: where does the pharmaceutical industry stand?
- Moderna’s Omicron booster receives MHRA approval
- AstraZeneca and Daiichi Sankyo receive FDA approval for lung cancer drug
- Achieving communication excellence by targeting the right channel at the right time
- Environment: where does the pharmaceutical industry stand?
- FDA approves Incyte’s Pemazyre as first targeted drug for bile duct cancer
- Novartis reports death of two patients treated with Zolgensma
- Pfizer, Mylan move ahead with generics merger and spin-out
PMHub
Six Degrees Medical Consulting
For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...
Latest intelligence
- Environment: where does the pharmaceutical industry stand?
- ...
- The communication challenge of helping he next generation to be healthier
- As the pressure on the health service increases the health of the next generation is vital for everyone. How do we show positive attitudes and change behaviour while future proofing...
- Are we losing sight of what the democratisation of healthcare really looks like?
- We have a core responsibility as healthcare communicators to consistently drive for better inclusion, engagement and compliance. What does the ‘democratisation of healthcare’ really look like?...
